According to Health Services Research, approaching 80% of lifetime healthcare expenditures occur after age 40.
Forever Labs was founded in 2015 with offices in Ann Arbor, Michigan. It is a longevity company set to transform the healthcare industry by banking healthy stem cells for future therapies that counteract age-related diseases such as stroke, heart disease, and osteoporosis, as well increasing healthspan overall. Mesenchymal stem cells (MSCs) are collected by a certified physician and after a straightforward, 15-minute outpatient procedure, the stem cells are cryogenically frozen and stored in an FDA-compliant clinical-grade biorepository. The cells are then available as needed.
The company has closed $2 million in financing from Northwestern Mutual, Silicon Badia Ventures, Babel Ventures, Aaron Hirschhorn, founder and CEO of DogVacay, and notable members of the medical community including Dr. Michael Dobryansky, Dr. Timothy Davis, Dr. Michael Schenden, among others. Forever Labs plans to dedicate the resources to stem cell research and to accelerating the brand development.
“We created Forever Labs as a solution to store those younger [stem] cells now, so people will live healthier and longer lives. We’re thrilled to have the support of such a well-respected group of investors that are helping us bring this vision to scale.” – Steven Clausnitzer, co-founder and CEO.
“As someone that has been developing therapies using these cells for more than 15 years, I expect that stem cell banking will become a cornerstone of good medicine. There is simply too much value in them that is lost to time,” said Mark Katakowski, PhD, co-founder and President.
“The Forever Labs team is on the forefront of stem cell research and pushing the science for longevity forward, I myself have personally experienced the breakthroughs of this science with knee and back injuries,” said Aaron Hirschhorn, founder and CEO of DogVacay. “The discovery and dedication to finding innovative ways to help health maintenance as opposed to disease treatment has life-changing implications, and I look forward to working closely with the team as this technology is propelled forward by increased adoption.”